RALEIGH, N.C.–(BUSINESS WIRE)–SignalPath, a healthcare technology company reimagining the execution of clinical trials, announces the closing of their Series B funding round of $18M. The round was completed by existing investors with a total raise of capital to date of $35M. This funding round supports the rapid growth of its network of leading community and academic health systems using the platform to manage their research portfolio as well as the continued expansion of SignalPath’s product suite. Furthermore, the funding will prepare for the upcoming launch of SignalPath’s technology-enabled hybrid clinical trials across its research footprint.
“As a founding member of the Board of Directors at SignalPath, I have been thrilled to see the rapid adoption of their innovative, intuitive research platform that drives ease and efficiency of trial execution at leading research sites around the country,” says Dr. Bob Harrington, Professor of Medicine, Stanford University. “I am particularly excited about the upcoming launch of novel trials that will reduce cost, drive transparency and generate new insights.”
SignalPath’s suite of tools for sites is comprehensive, covering the needs of all stakeholders in the site ecosystem including coordinator, finance, regulatory and management teams. The product has expanded beyond its original focus as a Clinical Trial Management System (CTMS) to address key pain points from study design to trial startup to study oversight for site management organizations. In light of the large network of sites and users on the platform, along with the breadth of the offering, SignalPath is now uniquely positioned to reimagine trials themselves. The funding will support growth in the research teams and products required to realize that vision.
“Since the very beginning we believed that by providing intuitive software tools to research professionals that solved their key pain points and reduced complexity, we would drive efficiency, improve quality, and increase transparency across the research ecosystem,” says Dr. Brad Hirsch, Co-Founder & CEO at SignalPath. “Now that we have a powerful network of large, interconnected sites on our technology, we can realize our ultimate vision of developing new insights through trials at our sites that were previously impossible to conduct.”
SignalPath is the premier clinical trial technology partner for research sites and sponsors, focused on improving the ease and efficiency of trial execution and management. Supporting over 2,500 trials across 250 sites and 3,000 active users, SignalPath is the industry standard that addresses key pain points in the conduct of trials. To learn more about SignalPath’s site and trial solutions, please visit www.signalpath.com.
SignalPath LLC | Daniel Quinn | 919-355-0460 | firstname.lastname@example.org